News
SCYX
1.740
-0.57%
-0.010
Scynexis: New rVVC Label And Black-Boxed Warning, Maintaining A Sell Rating
Seeking Alpha · 01/09 07:41
SCYNEXIS's Return On Capital Employed Overview
Benzinga · 12/13/2022 14:48
SCYNEXIS Announces FDA Approval Of Second Indication For BREXAFEMME For Reduction In Incidence Of Recurrent Vulvovaginal Candidiasis
Benzinga · 12/01/2022 13:04
BRIEF-Scynexis Announces FDA Approval Of Second Indication For Brexafemme® (Ibrexafungerp Tablets) For Reduction In Incidence Of Recurrent Vulvovaginal Candidiasis
Reuters · 12/01/2022 13:03
Scynexis Says US FDA Approves Second Indication for Brexafemme
Scynexis Says US FDA Approves Second Indication for Brexafemme
MT Newswires · 12/01/2022 10:29
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.Ibrexafungerp, a first-in-class, broad-spectrum ...
GlobeNewswire · 11/17/2022 13:30
SCYNEXIS Q3 EPS $(0.62) Misses $(0.50) Estimate, Sales $1.56M Miss $2.07M Estimate
Benzinga · 11/09/2022 12:21
SCYNEXIS GAAP EPS of -$0.62 misses by $0.12, revenue of $1.56M misses by $0.5M
Seekingalpha · 11/09/2022 12:07
-- Earnings Flash (SCYX) SCYNEXIS Posts Q3 Revenue $1.6M, vs. Street Est of $2.1M
-- Earnings Flash (SCYX) SCYNEXIS Posts Q3 Revenue $1.6M, vs. Street Est of $2.1M
MT Newswires · 11/09/2022 07:08
Notable earnings before Wednesday's open
Seekingalpha · 11/08/2022 15:36
SCYNEXIS Announces Publication Of Review Article Highlighting Ibrexafungerp As A Potential Novel Treatment For Invasive Mold Infections In The Journal Of Fungi
Benzinga · 11/07/2022 13:31
BRIEF-Pooled Data From The Pivotal Phase 3 Vanish Program Published In The Journal Of Women’S Health
Reuters · 11/03/2022 12:45
Pooled Data From The Pivotal Phase 3 VANISH Program Published In The Journal Of Women's Health Demonstrate Significant Efficacy Of Ibrexafungerp Over Placebo For Treatment Of Vaginal Yeast Infection
Benzinga · 11/03/2022 12:33
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Benzinga · 11/01/2022 20:01
BRIEF-Scynexis To Report Q3 Financial Results
Reuters · 11/01/2022 13:07
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference ...
GlobeNewswire · 11/01/2022 12:30
Scynexis appoints Ivor Macleod as CFO
Seekingalpha · 10/25/2022 13:13
Biopharma Veteran Ivor Macleod Joins SCYNEXIS As Chief Financial Officer
Benzinga · 10/25/2022 12:31
BRIEF-Scynexis Presents Positive Interim Data Of Oral Ibrexafungerp For Severe Fungal Infections
Reuters · 10/24/2022 12:43
SCYNEXIS Presents Positive Interim Data Of Oral Ibrexafungerp For Severe Fungal Infections From Ongoing Phase 3 FURI Study During IDWeek 2022 October 19-23
Benzinga · 10/24/2022 12:36
More
Webull provides a variety of real-time SCYX stock news. You can receive the latest news about Scynexis through multiple platforms. This information may help you make smarter investment decisions.
About SCYX
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. It has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). It is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.